Summary & Overview
CPT 0041U: Lyme ImmunoBlot IgM (IGeneX)
CPT code 0041U designates the proprietary Lyme ImmunoBlot IgM assay produced by IGeneX Inc., a laboratory serology test that detects IgM antibodies to five recombinant protein groups for identification of Borrelia burgdorferi, the causative agent of Lyme disease. As a PLA code, 0041U is unique to a single manufacturer and lab and is used where clinicians and payers need a specific identifier for this proprietary assay. Nationally, PLA codes like 0041U matter because they enable tracking, billing, and policy decisions for tests that do not have generic CPT equivalents.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical context for the assay, expected sites of service (clinical laboratories and independent diagnostic testing facilities), and which payers are addressed. The publication outlines benchmarks and payment considerations where available, clarifies coding and billing implications of using a PLA code, and situates the assay within laboratory diagnostic workflows for suspected Lyme disease. Data not available in the input is identified where applicable.
Billing Code Overview
CPT code 0041U is a Proprietary Laboratory Analyses (PLA) code describing the Lyme ImmunoBlot IgM test from IGeneX Inc. The test detects IgM antibodies to five recombinant protein groups to identify Borrelia burgdorferi, the tick-borne bacterium that causes Lyme disease.
Service type: Laboratory / Infectious disease serology
Typical site of service: Clinical laboratory or independent diagnostic testing facility (IDTF)
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient presents to an outpatient infectious disease clinic with a recent history of a tick bite and a 2-week history of fever, fatigue, headache, and an expanding erythematous skin lesion. The clinician documents concern for early Lyme disease and orders serologic testing to evaluate for acute infection. The specimen is collected by phlebotomy at the clinic and sent to IGeneX, Inc. for proprietary testing. The laboratory performs the Lyme ImmunoBlot IgM (0041U) to detect IgM antibodies against five recombinant Borrelia burgdorferi protein groups. Results are reported to the ordering provider electronically; interpretation includes band reactivity and an IgM positivity assessment. Typical workflow steps: order placed in the electronic health record, specimen drawn and accessioned, couriered to the reference lab, test performed by IGeneX, result finalized and routed back to the clinician, and follow-up plan documented in the outpatient visit note.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | HCPCS/CPT unmodified | Use when no modifier applies to the laboratory service |
11 | Office/Outpatient |